Duty Hour Restrictions Don't Impair Thyroid Surgery Outcomes

Share this content:
Duty Hour Restrictions Don't Impair Thyroid Surgery Outcomes
Duty Hour Restrictions Don't Impair Thyroid Surgery Outcomes

FRIDAY, Feb. 10, 2017 (HealthDay News) -- Implementation of duty hour reform does not negatively impact thyroid and parathyroid procedure outcomes, according to a study published online Feb. 9 in JAMA Otolaryngology-Head & Neck Surgery.

Aaron Smith, M.D., from the University of Tennessee Health Science Center in Memphis, and colleagues conducted a retrospective cross-sectional analysis of the National Inpatient Sample for procedure codes associated with thyroid and parathyroid procedures for 2000 to 2002 and 2006 to 2008. Hospitals were categorized as nonteaching hospitals (NTHs), teaching hospitals without otolaryngology programs (THs), and teaching hospitals with otolaryngology programs (THs-OTO).

Data were included for 34,685 head and neck procedures in 2000 to 2002 and 39,770 procedures in 2006 to 2008 (14.7 percent increase). The researchers found that in 2006 to 2008, THs-OTO contributed a greater share of procedures (from 18 to 25 percent). Compared with 2000 to 2002, length of stay remained constant in 2006 to 2008 (21 days) but there was an increase in total hospital charges (from $12,978 to $23,708; P < 0.001). There were overall increases in the rates of postoperative hematoma, hypoparathyroidism, and unintentional vessel lacerations (odds ratios, 1.21, 1.27, and 1.36) with NTHs, THs, and THs-OTO (odds ratios, 1.26, 1.65, and 1.98) accounting for these differences, respectively. Following a decrease in the THs-OTO mortality rate (odds ratio, 0.34), there was a decrease in overall mortality (odds ratio, 0.66).

"This finding refutes the concern that duty hour restrictions result in poorer overall outcomes," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »